Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Neuronetics stock price, quote, forecast and news

STIM
US64131A1051
A2JPMY

Price

0.75
Today +/-
-0.03
Today %
-3.92 %
P

Neuronetics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Neuronetics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Neuronetics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Neuronetics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Neuronetics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Neuronetics Stock Price History

DateNeuronetics Price
9/27/20240.75 undefined
9/26/20240.78 undefined
9/25/20240.79 undefined
9/24/20240.84 undefined
9/23/20240.88 undefined
9/20/20240.93 undefined
9/19/20240.95 undefined
9/18/20240.94 undefined
9/17/20240.95 undefined
9/16/20240.78 undefined
9/13/20240.73 undefined
9/12/20240.74 undefined
9/11/20240.74 undefined
9/10/20240.78 undefined
9/9/20240.78 undefined
9/6/20240.78 undefined
9/5/20240.78 undefined
9/4/20240.82 undefined
9/3/20240.87 undefined
8/30/20240.88 undefined

Neuronetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Neuronetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neuronetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neuronetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Neuronetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Neuronetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Neuronetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neuronetics’s growth potential.

Neuronetics Revenue, EBIT and net profit per share

DateNeuronetics RevenueNeuronetics EBITNeuronetics Net Income
2027e131.78 M undefined-612,000 undefined0 undefined
2026e101.93 M undefined-7.69 M undefined-12.36 M undefined
2025e89.1 M undefined-14.25 M undefined-19.32 M undefined
2024e79.48 M undefined-22.11 M undefined-27.12 M undefined
202371.35 M undefined-30.55 M undefined-30.19 M undefined
202265.21 M undefined-35.11 M undefined-37.16 M undefined
202155.31 M undefined-27.56 M undefined-31.19 M undefined
202049.24 M undefined-22.31 M undefined-27.45 M undefined
201962.66 M undefined-26.93 M undefined-29.04 M undefined
201852.78 M undefined-19.83 M undefined-24.1 M undefined
201740.43 M undefined-13.61 M undefined-16.06 M undefined
201634.23 M undefined-9.34 M undefined-11.23 M undefined

Neuronetics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e
34405262495565717989101131
-17.6530.0019.23-20.9712.2418.189.2311.2712.6613.4829.70
79.4175.0076.9275.8175.5178.1875.3871.83----
27304047374349510000
-9-13-19-26-22-27-35-30-22-14-70
-26.47-32.50-36.54-41.94-44.90-49.09-53.85-42.25-27.85-15.73-6.93-
-11-16-24-29-27-31-37-30-27-19-120
-45.4550.0020.83-6.9014.8119.35-18.92-10.00-29.63-36.84-
16.2516.258.9518.3818.8425.4826.928.660000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Neuronetics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Neuronetics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
1729.1104.675.74994.170.359.68
3.64.35.66.67.27.713.615.78
0000.81.92.31.82.96
1.72.52.42.83.76.68.98.09
0.61.11.82.53.34.64.27.28
22.937114.488.465.1115.398.893.79
1.61.41.44.95.35.15.34.78
00000000
0001.72.311.81.64.46
00000000
00000000
0.30.61.25.16911.212.8
1.922.611.713.625.918.122.04
24.839117100.178.7141.2116.9115.83
               
172.3187.10.20.20.20.30.30.29
3.84.3291.9297.8302.8393.6402.7409.98
-180.9-196.9-221-250.1-277.5-308.7-345.9-376.08
00000000
00000000
-4.8-5.571.147.925.585.257.134.19
1.52.53.84.63.74.32.44.75
67.57.197.37.914.912.39
1.322.72.82.63.52.82.67
00000000
4.50011.30013.10
13.31213.627.713.615.733.219.81
16.13030.419.934.635.322.859.28
00000000
0.22.424.74.953.82.55
16.332.432.424.639.540.326.661.83
29.644.44652.353.15659.881.64
24.838.9117.1100.278.6141.2116.9115.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Neuronetics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Neuronetics's financial health and stability.

Assets

Neuronetics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Neuronetics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Neuronetics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Neuronetics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-11-16-24-29-27-31-37-30
00010112
00000000
13-1-6-8-6-4-14
015710161817
21223334
00000000
-8-11-20-30-28-27-30-32
00-100-2-3-2
00-100-96-1
00000-7101
00000000
5100020023
014100208300
423972283022
--1.00-3.00-----1.00
00000000
-31275-28-2645-23-10
-8.86-11.73-21.6-31.29-29.12-30.33-34.01-34.41
00000000

Neuronetics stock margins

The Neuronetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neuronetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neuronetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Neuronetics's sales revenue. A higher gross margin percentage indicates that the Neuronetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Neuronetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Neuronetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neuronetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neuronetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neuronetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Neuronetics Margin History

Neuronetics Gross marginNeuronetics Profit marginNeuronetics EBIT marginNeuronetics Profit margin
2027e72.47 %-0.46 %0 %
2026e72.47 %-7.55 %-12.13 %
2025e72.47 %-15.99 %-21.68 %
2024e72.47 %-27.81 %-34.12 %
202372.47 %-42.82 %-42.31 %
202276.25 %-53.84 %-56.99 %
202178.94 %-49.83 %-56.39 %
202076.54 %-45.31 %-55.75 %
201975.44 %-42.98 %-46.35 %
201876.41 %-37.57 %-45.66 %
201776.18 %-33.66 %-39.72 %
201680.66 %-27.29 %-32.81 %

Neuronetics Stock Sales Revenue, EBIT, Earnings per Share

The Neuronetics earnings per share therefore indicates how much revenue Neuronetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neuronetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neuronetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neuronetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neuronetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neuronetics Revenue, EBIT and net profit per share

DateNeuronetics Sales per ShareNeuronetics EBIT per shareNeuronetics Earnings per Share
2027e4.35 undefined0 undefined0 undefined
2026e3.36 undefined0 undefined-0.41 undefined
2025e2.94 undefined0 undefined-0.64 undefined
2024e2.62 undefined0 undefined-0.9 undefined
20232.49 undefined-1.07 undefined-1.05 undefined
20222.42 undefined-1.31 undefined-1.38 undefined
20212.17 undefined-1.08 undefined-1.22 undefined
20202.61 undefined-1.18 undefined-1.46 undefined
20193.41 undefined-1.47 undefined-1.58 undefined
20185.9 undefined-2.22 undefined-2.69 undefined
20172.49 undefined-0.84 undefined-0.99 undefined
20162.11 undefined-0.57 undefined-0.69 undefined

Neuronetics business model

Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.com.

Neuronetics SWOT Analysis

Strengths

Neuronetics Inc possesses several strengths that contribute to its success:

Neuronetics Inc has developed an innovative technology for the treatment of neurological disorders.

The company holds significant intellectual property rights, protecting its technology and products.

Neuronetics Inc has built a strong brand reputation in the medical device industry, resulting in customer trust and loyalty.

The company has a dedicated team of skilled professionals who contribute to the research, development, and commercialization of its products.

Weaknesses

Despite its strengths, Neuronetics Inc faces certain weaknesses that need to be addressed:

The company currently offers a limited range of products, which could restrict its market potential.

Neuronetics Inc primarily focuses on a specific market segment, which makes it vulnerable to fluctuations in that particular market.

Opportunities

There are several opportunities that Neuronetics Inc can capitalize on:

The company can explore new geographic markets and expand its product offerings to reach a larger customer base.

Neuronetics Inc can establish strategic partnerships and collaborations with other medical device companies to leverage their expertise and resources.

Threats

Neuronetics Inc should be cautious of the following threats:

The company operates in a highly competitive market with several established players, which may pose challenges in terms of market share and pricing.

Changes in regulatory requirements and policies can affect the manufacturing, distribution, and marketing of Neuronetics Inc's products.

Neuronetics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Neuronetics historical P/E ratio, EBIT, and P/S ratio.

Neuronetics shares outstanding

The number of shares was Neuronetics in 2023 — This indicates how many shares 28.658 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neuronetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neuronetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neuronetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neuronetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Neuronetics.

Neuronetics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.28 -0.33  (-19.83 %)2024 Q2
3/31/2024-0.32 -0.27  (14.61 %)2024 Q1
12/31/2023-0.27 -0.19  (28.71 %)2023 Q4
9/30/2023-0.32 -0.33  (-4.63 %)2023 Q3
6/30/2023-0.36 -0.17  (52.14 %)2023 Q2
3/31/2023-0.4 -0.38  (3.99 %)2023 Q1
12/31/2022-0.39 -0.3  (22.86 %)2022 Q4
9/30/2022-0.43 -0.28  (34.82 %)2022 Q3
6/30/2022-0.42 -0.39  (7.16 %)2022 Q2
3/31/2022-0.41 -0.41  (-0.54 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Neuronetics stock

Eulerpool World ESG Rating (EESG©)

29/ 100

🌱 Environment

33

👫 Social

26

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Neuronetics list of shareholders

%
Name
Stocks
Change
Date
9.13950 % Cannell Capital, LLC2,769,268-64,71412/31/2023
8.37326 % Archon Capital Management LLC2,537,097-340,60912/31/2023
5.08047 % Divisadero Street Capital Management, LP1,539,3821,539,3823/26/2024
4.67895 % Balyasny Asset Management LP1,417,72221,23912/31/2023
4.46582 % The Vanguard Group, Inc.1,353,144012/31/2023
3.71777 % Silvercrest Asset Management Group LLC1,126,484012/31/2023
3.68330 % Kent Lake Capital LLC1,116,041-1,213,24612/31/2023
2.56109 % First Eagle Investment Management, L.L.C.776,009012/31/2023
2.50960 % Parian Global Management LP760,410-69,86312/31/2022
2.45758 % Medical Strategy GmbH744,64750,8473/31/2023
1
2
3
4
5
...
10

Neuronetics Executives and Management Board

Mr. Keith Sullivan65
Neuronetics President, Chief Executive Officer, Director (since 2020)
Compensation 2.43 M
Mr. Stephen Furlong59
Neuronetics Chief Financial Officer, Executive Vice President, Treasurer
Compensation 1.35 M
Mr. W. Andrew Macan50
Neuronetics Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Compensation 1.17 M
Mr. Robert Cascella69
Neuronetics Independent Non-Executive Chairman of the Board
Compensation 251,250
Mr. Glenn Muir64
Neuronetics Independent Director
Compensation 182,499
1
2
3

Neuronetics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Greenbrook Tms Stock
Greenbrook Tms
SupplierCustomer-0,030,090,750,900,880,88
Teijin Stock
Teijin
SupplierCustomer-0,53-0,35-0,190,230,860,77
1

Most common questions regarding Neuronetics

What values and corporate philosophy does Neuronetics represent?

Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.

In which countries and regions is Neuronetics primarily present?

Neuronetics Inc is primarily present in the United States.

What significant milestones has the company Neuronetics achieved?

Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.

What is the history and background of the company Neuronetics?

Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.

Who are the main competitors of Neuronetics in the market?

The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.

In which industries is Neuronetics primarily active?

Neuronetics Inc is primarily active in the healthcare industry.

What is the business model of Neuronetics?

The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.

What is the P/E ratio of Neuronetics 2024?

The Neuronetics P/E ratio is -0.79.

What is the P/S ratio of Neuronetics 2024?

The Neuronetics P/S ratio is 0.27.

What is the AlleAktien quality score of Neuronetics?

The AlleAktien quality score for Neuronetics is 4/10.

What is the revenue of Neuronetics 2024?

The expected Neuronetics revenue is 79.48 M USD.

How high is the profit of Neuronetics 2024?

The expected Neuronetics profit is -27.12 M USD.

What is the business model of Neuronetics

Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.

What is the Neuronetics dividend?

Neuronetics pays a dividend of 0 USD distributed over payouts per year.

How often does Neuronetics pay dividends?

The dividend cannot currently be calculated for Neuronetics or the company does not pay out a dividend.

What is the Neuronetics ISIN?

The ISIN of Neuronetics is US64131A1051.

What is the Neuronetics WKN?

The WKN of Neuronetics is A2JPMY.

What is the Neuronetics ticker?

The ticker of Neuronetics is STIM.

How much dividend does Neuronetics pay?

Over the past 12 months, Neuronetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuronetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Neuronetics?

The current dividend yield of Neuronetics is .

When does Neuronetics pay dividends?

Neuronetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neuronetics?

Neuronetics paid dividends every year for the past 0 years.

What is the dividend of Neuronetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neuronetics located?

Neuronetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neuronetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neuronetics from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Neuronetics pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Neuronetics in the year 2023?

In the year 2023, Neuronetics distributed 0 USD as dividends.

In which currency does Neuronetics pay out the dividend?

The dividends of Neuronetics are distributed in USD.

All fundamentals about Neuronetics

Our stock analysis for Neuronetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuronetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.